Ionis Pharmaceuticals Inc
IONS76.090USD
+2.970+4.06%
Handelsschluss 11/21, 16:00（ET）Kurse um 15 Minuten verzögert
12.26BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Ionis Pharmaceuticals Inc Unternehmen
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Ionis Pharmaceuticals Inc Informationen
BörsenkürzelIONS
Name des UnternehmensIonis Pharmaceuticals Inc
IPO-datumMay 17, 1991
CEODr. Brett P. Monia, Ph.D.
Anzahl der mitarbeiter1069
WertpapierartOrdinary Share
GeschäftsjahresendeMay 17
Addresse2855 Gazelle Court
StadtCARLSBAD
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl92010
Telefon17609319200
Websitehttps://www.ionis.com/
BörsenkürzelIONS
IPO-datumMay 17, 1991
CEODr. Brett P. Monia, Ph.D.
Führungskräfte von Ionis Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
179.57K
-0.24%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+2.68%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
--
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
59.66K
--
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
53.89K
-5.67%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
48.83K
-14.08%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
47.47K
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
36.33K
--
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
30.57K
-18.30%
Ms. Shannon L. Devers
Ms. Shannon L. Devers
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.49K
+9.77%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
179.57K
-0.24%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+2.68%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
--
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
59.66K
--
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
53.89K
-5.67%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
48.83K
-14.08%
Umsatzaufteilung
Währung: USDAktualisiert: Tue, Mar 4
Währung: USDAktualisiert: Tue, Mar 4
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Aktionärsstatistik
Aktualisiert: Wed, Nov 19
Aktualisiert: Wed, Nov 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
14.63%
The Vanguard Group, Inc.
10.15%
T. Rowe Price Investment Management, Inc.
8.12%
Capital World Investors
7.85%
BlackRock Institutional Trust Company, N.A.
5.22%
Andere
54.02%
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
14.63%
The Vanguard Group, Inc.
10.15%
T. Rowe Price Investment Management, Inc.
8.12%
Capital World Investors
7.85%
BlackRock Institutional Trust Company, N.A.
5.22%
Andere
54.02%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
68.55%
Investment Advisor/Hedge Fund
19.48%
Hedge Fund
13.84%
Research Firm
2.62%
Pension Fund
1.04%
Bank and Trust
0.81%
Individual Investor
0.75%
Sovereign Wealth Fund
0.28%
Family Office
0.02%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
815
172.95M
106.78%
-7.24M
2025Q2
801
185.40M
116.34%
+8.33M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
2023Q3
763
145.13M
101.24%
-1.40M
2023Q2
770
142.08M
99.29%
+364.04K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fidelity Management & Research Company LLC
23.64M
14.83%
+29.41K
+0.12%
Jun 30, 2025
The Vanguard Group, Inc.
16.68M
10.47%
+329.29K
+2.01%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
16.05M
10.07%
-126.81K
-0.78%
Jun 30, 2025
Capital World Investors
12.54M
7.87%
+178.19K
+1.44%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.73M
5.47%
-171.64K
-1.93%
Jun 30, 2025
Wellington Management Company, LLP
6.35M
3.98%
-2.07M
-24.60%
Jun 30, 2025
Bellevue Asset Management AG
7.85M
4.93%
--
--
Jun 30, 2025
State Street Investment Management (US)
4.53M
2.84%
-314.74K
-6.50%
Jun 30, 2025
Deep Track Capital LP
4.89M
3.07%
+327.34K
+7.17%
Jun 30, 2025
Two Sigma Investments, LP
4.46M
2.8%
+678.11K
+17.95%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Thu, Nov 6
Aktualisiert: Thu, Nov 6
Name
Anteil
Invesco Biotechnology & Genome ETF
4.15%
ARK Genomic Revolution ETF
3.61%
Virtus LifeSci Biotech Products ETF
3.06%
Invesco Dorsey Wright Healthcare Momentum ETF
2.45%
SPDR S&P Biotech ETF
2.11%
VanEck Morningstar SMID Moat ETF
1.89%
Tema Heart & Health ETF
1.62%
Capital Group US Small and Mid Cap ETF
1.34%
Direxion Daily S&P Biotech Bull 3X Shares
1.11%
iShares Biotechnology ETF
0.98%
Mehr Anzeigen
Invesco Biotechnology & Genome ETF
Anteil4.15%
ARK Genomic Revolution ETF
Anteil3.61%
Virtus LifeSci Biotech Products ETF
Anteil3.06%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil2.45%
SPDR S&P Biotech ETF
Anteil2.11%
VanEck Morningstar SMID Moat ETF
Anteil1.89%
Tema Heart & Health ETF
Anteil1.62%
Capital Group US Small and Mid Cap ETF
Anteil1.34%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil1.11%
iShares Biotechnology ETF
Anteil0.98%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Ionis Pharmaceuticals Inc?
Die fünf größten Anteilseigner von Ionis Pharmaceuticals Inc sind:
Fidelity Management & Research Company LLC hält 23.64M Aktien, was 14.83% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 16.68M Aktien, was 10.47% der Gesamtaktien entspricht.
T. Rowe Price Investment Management, Inc. hält 16.05M Aktien, was 10.07% der Gesamtaktien entspricht.
Capital World Investors hält 12.54M Aktien, was 7.87% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 8.73M Aktien, was 5.47% der Gesamtaktien entspricht.
Fidelity Management & Research Company LLC hält 23.64M Aktien, was 14.83% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 16.68M Aktien, was 10.47% der Gesamtaktien entspricht.
T. Rowe Price Investment Management, Inc. hält 16.05M Aktien, was 10.07% der Gesamtaktien entspricht.
Capital World Investors hält 12.54M Aktien, was 7.87% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 8.73M Aktien, was 5.47% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Ionis Pharmaceuticals Inc?
Die drei wichtigsten Anteilseigner-Typen von Ionis Pharmaceuticals Inc sind:
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
T. Rowe Price Investment Management, Inc.
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
T. Rowe Price Investment Management, Inc.
Wie viele Institutionen halten Anteile an Ionis Pharmaceuticals Inc (IONS)?
Mit Stand vom 2025Q3 halten 815 Institutionen Anteile an Ionis Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 172.95M, was 106.78% der Gesamtanteile entspricht. Im Vergleich zum 2025Q2 ist der institutionelle Aktienbesitz um -9.56% gestiegen.
Was ist die größte Einnahmequelle von Ionis Pharmaceuticals Inc?
Am FY2020 erzielte das Geschäft mit R&D revenue under collaborative agreements für Ionis Pharmaceuticals Inc den höchsten Umsatz in Höhe von 364.56M, was 49.99% des Gesamtumsatzes entspricht.
